CDNA•businesswire•
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Summary
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025. Preliminary Fourth Quarter 2025 Financial Results Revenue of approximately $108 million, an increase of 25% ye
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 12, 2026 by businesswire